Allocord market forecast points to steady growth through 2035
The Business Research Company says the Allocord market is set for steady expansion through 2026-2035, driven by rising rare-disease diagnoses, personalized medicine, and higher healthcare spending. North America led the market in 2025, while Asia-Pacific is expected to grow fastest during the forecast period.
Why it matters: - Allocord is positioned around treatments for severe combined immunodeficiency and other rare genetic diseases, making the market relevant to a small but high-need patient group. - The forecast points to demand coming from specialty care, regenerative medicine, and cord blood banking as healthcare systems invest more in rare-disease treatment options.
What happened: - The Business Research Company published an Allocord market report dated October 29, 2026. - The report forecasts the Allocord market for 2026-2035 and highlights growth drivers, regional trends, and segment opportunities. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.
The details: - The report links past growth to limited treatment alternatives for SCID, heavy reliance on bone marrow transplants, better diagnosis of immune disorders, expansion of hospital transplant programs, and unmet needs in enzyme replacement therapies. - Expected growth drivers include rising diagnoses of inherited immunodeficiencies, advanced biologic therapies, more specialty treatment centers, higher funding for rare diseases, and better long-term patient outcomes. - The report says Allocord therapies will see broader use in cellular and enzyme therapies, rare genetic disorders, personalized immune treatments, and hospital-based specialty care programs. - Allocord is described as a therapeutic solution for SCID and other rare genetic conditions that provides enzyme replacement therapy to help the immune system function properly. - The report says rising chronic disease prevalence is also supporting demand because Allocord offers cord blood banking services that can support stem cell-based regenerative therapies. - Allergy UK reported in April 2024 that more than 21 million people in the UK have allergies, and projections suggest half of Europe’s population will have at least one allergy by 2026. - Growing interest in personalized medicine is another driver, supported by genomics, precision diagnostics, and demand for more effective care. - The Personalized Medicine Coalition said in February 2024 that the US Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from 6 in 2022. - Healthcare spending growth is expected to support the market as populations age, chronic disease rates rise, and treatment costs increase. - The UK Office for National Statistics reported in May 2024 that total healthcare spending rose 5.6% nominally in 2023, a 0.9% increase from 2022. - The market coverage spans Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report says 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, and future trend analysis. - The report includes a free sample download and a full report link: Download the sample report and View the full report.
Between the lines: - The report frames Allocord as part of a broader shift toward personalized and regenerative medicine rather than a standalone product story. - The strongest demand signals come from rare-disease care and specialty treatment infrastructure, which suggests growth depends on both clinical adoption and healthcare system capacity. - North America’s current lead and Asia-Pacific’s forecast growth suggest a mature market with room for geographic expansion rather than a uniform global rollout.
What's next: - The report expects continued market expansion through 2035 as biologic therapies, specialty centers, and rare-disease funding scale up. - Wider use of cord blood banking and personalized treatment approaches could deepen Allocord’s role in regenerative and immune-disorder care. - The company is steering readers to its expert contacts and report materials for more detail.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Latin America Reporter
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.